Cardiometabolic aspects of polycystic ovarian syndrome

Li Wei Cho, Harpal S. Randeva, Stephen Atkin

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

It is estimated that 6%-7% of women of reproductive age have polycystic ovarian syndrome (PCOS). Women with this condition exhibit an adverse cardiovascular risk profile, characteristic of the cardiometabolic syndrome and given the high prevalence of PCOS in the female population, this condition may contribute towards the acceleration of cardiovascular disease among young women. This article summarizes the recent development and findings in the cardiometabolic abnormalities in patients with PCOS. Patients with PCOS have the clinical features of oligomenorrhoea, hirsutism and infertility; however, they also exhibit hyperinsulinemia, obesity, hypertension, dyslipidemia, and an increased pro-thrombotic state. They have an increased risk of type 2 diabetes and impaired glucose tolerance, and sleep apnea is also found more commonly in this population. However, despite the presence of cardiovascular risk factors and increased surrogate markers of cardiovascular disease it is unclear if they have accelerated atherosclerosis. End point studies are currently lacking and the available evidence are conflicting. Adipose tissue has emerged as an important endocrine organ over the last decade and gained recognition in having an important role in the cardiometabolic syndrome. Adiponectin that is secreted exclusively by adipocytes has recently been recognized as an important marker of cardiometabolic syndrome, obesity, type 2 diabetes, and coronary artery disease. Other adipocytokines like leptin and resistin have also recently been recognized. This article will address the current evidence for the adverse cardiovascular risk in PCOS and the other factors that may be implicated. Finally the therapeutic options for treatment will be discussed.

Original languageEnglish
Pages (from-to)55-63
Number of pages9
JournalVascular Health and Risk Management
Volume3
Issue number1
Publication statusPublished - 2007
Externally publishedYes

Fingerprint

Polycystic Ovary Syndrome
Type 2 Diabetes Mellitus
Cardiovascular Diseases
Obesity
Oligomenorrhea
Resistin
Hirsutism
Adipokines
Glucose Intolerance
Adiponectin
Sleep Apnea Syndromes
Hyperinsulinism
Dyslipidemias
Leptin
Adipocytes
Infertility
Population
Adipose Tissue
Coronary Artery Disease
Atherosclerosis

Keywords

  • Cardiometabolic syndrome
  • Cardiovascular disease
  • Polycystic ovarian syndrome

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hematology
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

Cardiometabolic aspects of polycystic ovarian syndrome. / Cho, Li Wei; Randeva, Harpal S.; Atkin, Stephen.

In: Vascular Health and Risk Management, Vol. 3, No. 1, 2007, p. 55-63.

Research output: Contribution to journalReview article

Cho, Li Wei ; Randeva, Harpal S. ; Atkin, Stephen. / Cardiometabolic aspects of polycystic ovarian syndrome. In: Vascular Health and Risk Management. 2007 ; Vol. 3, No. 1. pp. 55-63.
@article{2fbc73262854494a94ebfdad2bd07cae,
title = "Cardiometabolic aspects of polycystic ovarian syndrome",
abstract = "It is estimated that 6{\%}-7{\%} of women of reproductive age have polycystic ovarian syndrome (PCOS). Women with this condition exhibit an adverse cardiovascular risk profile, characteristic of the cardiometabolic syndrome and given the high prevalence of PCOS in the female population, this condition may contribute towards the acceleration of cardiovascular disease among young women. This article summarizes the recent development and findings in the cardiometabolic abnormalities in patients with PCOS. Patients with PCOS have the clinical features of oligomenorrhoea, hirsutism and infertility; however, they also exhibit hyperinsulinemia, obesity, hypertension, dyslipidemia, and an increased pro-thrombotic state. They have an increased risk of type 2 diabetes and impaired glucose tolerance, and sleep apnea is also found more commonly in this population. However, despite the presence of cardiovascular risk factors and increased surrogate markers of cardiovascular disease it is unclear if they have accelerated atherosclerosis. End point studies are currently lacking and the available evidence are conflicting. Adipose tissue has emerged as an important endocrine organ over the last decade and gained recognition in having an important role in the cardiometabolic syndrome. Adiponectin that is secreted exclusively by adipocytes has recently been recognized as an important marker of cardiometabolic syndrome, obesity, type 2 diabetes, and coronary artery disease. Other adipocytokines like leptin and resistin have also recently been recognized. This article will address the current evidence for the adverse cardiovascular risk in PCOS and the other factors that may be implicated. Finally the therapeutic options for treatment will be discussed.",
keywords = "Cardiometabolic syndrome, Cardiovascular disease, Polycystic ovarian syndrome",
author = "Cho, {Li Wei} and Randeva, {Harpal S.} and Stephen Atkin",
year = "2007",
language = "English",
volume = "3",
pages = "55--63",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Cardiometabolic aspects of polycystic ovarian syndrome

AU - Cho, Li Wei

AU - Randeva, Harpal S.

AU - Atkin, Stephen

PY - 2007

Y1 - 2007

N2 - It is estimated that 6%-7% of women of reproductive age have polycystic ovarian syndrome (PCOS). Women with this condition exhibit an adverse cardiovascular risk profile, characteristic of the cardiometabolic syndrome and given the high prevalence of PCOS in the female population, this condition may contribute towards the acceleration of cardiovascular disease among young women. This article summarizes the recent development and findings in the cardiometabolic abnormalities in patients with PCOS. Patients with PCOS have the clinical features of oligomenorrhoea, hirsutism and infertility; however, they also exhibit hyperinsulinemia, obesity, hypertension, dyslipidemia, and an increased pro-thrombotic state. They have an increased risk of type 2 diabetes and impaired glucose tolerance, and sleep apnea is also found more commonly in this population. However, despite the presence of cardiovascular risk factors and increased surrogate markers of cardiovascular disease it is unclear if they have accelerated atherosclerosis. End point studies are currently lacking and the available evidence are conflicting. Adipose tissue has emerged as an important endocrine organ over the last decade and gained recognition in having an important role in the cardiometabolic syndrome. Adiponectin that is secreted exclusively by adipocytes has recently been recognized as an important marker of cardiometabolic syndrome, obesity, type 2 diabetes, and coronary artery disease. Other adipocytokines like leptin and resistin have also recently been recognized. This article will address the current evidence for the adverse cardiovascular risk in PCOS and the other factors that may be implicated. Finally the therapeutic options for treatment will be discussed.

AB - It is estimated that 6%-7% of women of reproductive age have polycystic ovarian syndrome (PCOS). Women with this condition exhibit an adverse cardiovascular risk profile, characteristic of the cardiometabolic syndrome and given the high prevalence of PCOS in the female population, this condition may contribute towards the acceleration of cardiovascular disease among young women. This article summarizes the recent development and findings in the cardiometabolic abnormalities in patients with PCOS. Patients with PCOS have the clinical features of oligomenorrhoea, hirsutism and infertility; however, they also exhibit hyperinsulinemia, obesity, hypertension, dyslipidemia, and an increased pro-thrombotic state. They have an increased risk of type 2 diabetes and impaired glucose tolerance, and sleep apnea is also found more commonly in this population. However, despite the presence of cardiovascular risk factors and increased surrogate markers of cardiovascular disease it is unclear if they have accelerated atherosclerosis. End point studies are currently lacking and the available evidence are conflicting. Adipose tissue has emerged as an important endocrine organ over the last decade and gained recognition in having an important role in the cardiometabolic syndrome. Adiponectin that is secreted exclusively by adipocytes has recently been recognized as an important marker of cardiometabolic syndrome, obesity, type 2 diabetes, and coronary artery disease. Other adipocytokines like leptin and resistin have also recently been recognized. This article will address the current evidence for the adverse cardiovascular risk in PCOS and the other factors that may be implicated. Finally the therapeutic options for treatment will be discussed.

KW - Cardiometabolic syndrome

KW - Cardiovascular disease

KW - Polycystic ovarian syndrome

UR - http://www.scopus.com/inward/record.url?scp=34249844769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249844769&partnerID=8YFLogxK

M3 - Review article

C2 - 17583175

AN - SCOPUS:34249844769

VL - 3

SP - 55

EP - 63

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

IS - 1

ER -